Trials / Not Yet Recruiting
Not Yet RecruitingNCT07045558
HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC
HAIC in Combination With Atezolizumab Plus Bevacizumab as Conversion Therapy in Unresectable Hepatocellular Carcinoma: a Single-arm, Prospective Study
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 28 (estimated)
- Sponsor
- RenJi Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Patients with unresectable HCC will be enrolled in the cohort and will receive the combination therapy of HAIC and atezolizumab plus bevacizumab. The objective response rate is the primary endpoint, and the secondary endpoint includes disease control rate, conversion rate, pathologic complete response, major pathologic response, progression-free survival, recurrence-free survival, overall survival, quality of life, and safety.
Conditions
Timeline
- Start date
- 2025-08-01
- Primary completion
- 2026-07-31
- Completion
- 2028-01-31
- First posted
- 2025-07-01
- Last updated
- 2025-07-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07045558. Inclusion in this directory is not an endorsement.